Bioxcel Therapeutics Inc (BTAI) Stock Price, Quote & News

Company Profile

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 475-238-6837

Website: www.bioxceltherapeutics.com

Address:

555 Long Wharf Drive, 12th Floor, New Haven, United States

wndyctyboy1975 May. 13 at 2:01 AM

$BTAI pretty soon back to 1.05?

0 · Reply

CoffeeRocks May. 12 at 12:29 PM

$ANVS $CODX $BTAI

1 · Reply

CoffeeRocks May. 12 at 11:09 AM

$BTAI $CNS $ANVS $VTVT $IMUX

0 · Reply

CoffeeRocks May. 11 at 7:36 PM

$BTAI $ACAD https://finance.yahoo.com/markets/stocks/articles/earnings-miss-acadia-pharmaceuticals-inc-112731765.html

0 · Reply

wndyctyboy1975 May. 11 at 4:48 PM

$BTAI maybe one day it will go up like it fell

0 · Reply

CoffeeRocks May. 11 at 2:26 PM

$CODX $VRAX $BTAI $PGEN $THC 1.5$-2.6$ not bad not bad

1 · Reply

CoffeeRocks May. 11 at 2:17 PM

$BTAI $CODX $INHD $INO $PGEN Let’s get IT!!!!!

0 · Reply

CoffeeRocks May. 11 at 11:39 AM

$BTAI $CODX $INHD $INO $PGEN Picks CODX fda approval at home tests BTAI earnings waiting for approval at 🏡 test INO earnings PGEN earnings

1 · Reply

CoffeeRocks May. 11 at 11:30 AM

$TRAW $VRAX $CODX $BTAI $INO Also TRAW could breakout

0 · Reply

CoffeeRocks May. 11 at 10:51 AM

$CODX $BTAI Following same pattern

0 · Reply

BioXcel Therapeutics Transcript: Investor update

Apr 17, 2026, 7:00 AM EDT - 26 days ago

BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting

Apr 9, 2026, 7:53 PM EDT - 4 weeks ago

Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders?

2026-04-08T11:09:11.000Z - 5 weeks ago

BioXcel Therapeutics enrolls first patients in BXCL501 trial

Apr 8, 2026, 7:00 AM EDT - 5 weeks ago

BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions

2026-04-02T10:12:16.000Z - 5 weeks ago

BioXcel Therapeutics price target lowered to $5 from $6 at H.C. Wainwright

2026-04-01T11:09:26.000Z - 6 weeks ago

BioXcel Therapeutics announces FDA acceptance of Igalmi sNDA

Apr 1, 2026, 7:00 AM EDT - 6 weeks ago

BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting

2026-03-27T11:20:13.000Z - 6 weeks ago

BioXcel Therapeutics reports Q4 EPS (58c), consensus (63c)

Mar 27, 2026, 7:00 AM EDT - 6 weeks ago

BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting

2026-03-17T12:06:20.000Z - 2 months ago

BioXcel Therapeutics initiated with a Buy at Rodman & Renshaw

Mar 11, 2026, 4:20 PM EDT - 2 months ago

BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering

Mar 10, 2026, 2:36 PM EDT - 2 months ago

BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering

2026-03-05T13:59:23.000Z - 2 months ago

BioXcel price target lowered to $6 from $10 at H.C. Wainwright

2026-03-05T12:48:55.000Z - 2 months ago

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

2026-03-05T12:26:21.000Z - 2 months ago

BioXcel Therapeutics announces results from Phase 2 trial of BXCL501

Mar 5, 2026, 7:00 AM EST - 2 months ago

BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal

Feb 27, 2026, 2:00 PM EST - 2 months ago

BioXcel Therapeutics Transcript: Status update

2026-02-19T12:16:19.000Z - 2 months ago

BioXcel Therapeutics to host KOL roundtable on Alzheimer’s dementia

Feb 19, 2026, 7:00 AM EST - 2 months ago

BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia

2026-02-12T12:14:02.000Z - 3 months ago

BioXcel completes updated market opportunity assessment for Igalmi

2026-01-20T12:06:39.000Z - 4 months ago

BioXcel Therapeutics submits sNDA to U.S. FDA for Igalmi

Jan 20, 2026, 7:00 AM EST - 4 months ago

BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting

Jan 15, 2026, 12:44 PM EST - 4 months ago

Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights

2026-01-12T12:21:09.000Z - 4 months ago

BioXcel Therapeutics appoints Pavao as acting CCO

Jan 12, 2026, 7:00 AM EST - 4 months ago

BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting

2026-01-07T12:05:31.000Z - 4 months ago

BioXcel Therapeutics planning to submit sNDA seeking FDA approval for IGALMI

Jan 7, 2026, 7:00 AM EST - 4 months ago

BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®

Dec 12, 2025, 9:00 AM EST - 5 months ago

BioXcel Therapeutics Transcript: AGM 2025

Dec 3, 2025, 7:00 AM EST - 5 months ago

Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions

2025-11-21T15:25:20.000Z - 6 months ago

BioXcel Therapeutics’ Igalmi supplement for new indication approved by FDA

2025-11-12T12:16:09.000Z - 6 months ago

BioXcel Therapeutics reports Q3 EPS ($2.18), consensus ($1.34)

Nov 12, 2025, 7:00 AM EST - 6 months ago

BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer's Disease

2025-10-14T11:05:08.000Z - 7 months ago

BioXcel announces results from correlation study from SERENITY At-Home trial

Oct 14, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes

Oct 13, 2025, 7:00 AM EDT - 7 months ago

BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation

2025-09-18T11:11:17.000Z - 8 months ago

BioXcel Therapeutics regains compliance with Nasdaq

Sep 18, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements

2025-09-15T12:45:17.000Z - 8 months ago

BioXcel Therapeutics says has raised $37.3M since July 1 under ATM offering

Sep 10, 2025, 2:00 PM EDT - 8 months ago

BioXcel Therapeutics Transcript: Study Result

Sep 10, 2025, 6:30 AM EDT - 8 months ago

BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia

Sep 8, 2025, 4:30 PM EDT - 8 months ago

BioXcel Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 7:00 AM EDT - 8 months ago

BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 8:00 AM EDT - 9 months ago

UPDATE -- BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 27, 2025, 8:00 AM EDT - 9 months ago

BioXcel Therapeutics Transcript: Study Update

Aug 27, 2025, 7:29 AM EDT - 9 months ago

BioXcel's agitation drug meets main goal in at-home study

Aug 27, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Announces SERENITY At-Home Pivotal Phase 3 Safety Trial Met its Primary Endpoint in Support of sNDA Submission for Label Expansion of IGALMI®

Aug 26, 2025, 4:00 PM EDT - 9 months ago

BioXcel Therapeutics To Announce Topline Results from SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia on August 27, 2025

Aug 19, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Announces Database Lock in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 18, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia

Aug 14, 2025, 1:00 PM EDT - 9 months ago

BioXcel Therapeutics Transcript: H.C. Wainwright & Co. “HCW@Home” Series 2025

Aug 13, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics to Participate in the H.C. Wainwright & Co. “HCW@Home” Series

Aug 12, 2025, 12:00 PM EDT - 9 months ago

BioXcel Therapeutics Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 12, 2025, 7:55 AM EDT - 9 months ago

BioXcel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Updates

Aug 11, 2025, 7:00 AM EDT - 9 months ago

BioXcel Therapeutics to Participate in Canaccord Genuity 45th Annual Growth Conference

Aug 6, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Announces Publication in Frontiers in Pharmacology on the Effects of Dexmedetomidine (the active ingredient in BXCL-501) on Stress-Mediated Behaviors in Non-clinical Studies

Aug 1, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Announces Last Patient Last Visit in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Jul 21, 2025, 7:00 AM EDT - 10 months ago

BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®

Jul 1, 2025, 7:00 AM EDT - 11 months ago

BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 8:01 AM EDT - 1 year ago

BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

May 27, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirement

May 12, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 27, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Reports Financial Results for the Fourth Quarter and Full Year 2024

Mar 11, 2025, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 7, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia

Mar 4, 2025, 4:15 PM EST - 1 year ago

BioXcel Therapeutics Announces Closing of $14 Million Registered Direct Offering

Mar 3, 2025, 3:33 PM EST - 1 year ago

BioXcel Therapeutics Announces $14 Million Registered Direct Offering

Mar 3, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer's Dementia

Feb 28, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2025, 7:00 AM EST - 1 year ago

BioXcel Therapeutics Announces Reverse Stock Split

Nov 22, 2024, 8:16 AM EST - 1 year ago

BioXcel Therapeutics Announces Pricing of $7.0 Million Public Offering

Nov 21, 2024, 4:47 PM EST - 1 year ago

BioXcel Therapeutics Announces Proposed Public Offering

Nov 14, 2024, 8:00 AM EST - 1 year ago

BioXcel Therapeutics Earnings Call Transcript: Q3 2024

Nov 8, 2024, 7:00 AM EST - 1 year ago

BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024

Oct 29, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics to Present at ThinkEquity Conference

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress Disorder

Sep 19, 2024, 7:00 AM EDT - 1 year ago

BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

wndyctyboy1975 May. 13 at 2:01 AM

$BTAI pretty soon back to 1.05?

0 · Reply

CoffeeRocks May. 12 at 12:29 PM

$ANVS $CODX $BTAI

1 · Reply

CoffeeRocks May. 12 at 11:09 AM

$BTAI $CNS $ANVS $VTVT $IMUX

0 · Reply

CoffeeRocks May. 11 at 7:36 PM

$BTAI $ACAD https://finance.yahoo.com/markets/stocks/articles/earnings-miss-acadia-pharmaceuticals-inc-112731765.html

0 · Reply

wndyctyboy1975 May. 11 at 4:48 PM

$BTAI maybe one day it will go up like it fell

0 · Reply

CoffeeRocks May. 11 at 2:26 PM

$CODX $VRAX $BTAI $PGEN $THC 1.5$-2.6$ not bad not bad

1 · Reply

CoffeeRocks May. 11 at 2:17 PM

$BTAI $CODX $INHD $INO $PGEN Let’s get IT!!!!!

0 · Reply

CoffeeRocks May. 11 at 11:39 AM

$BTAI $CODX $INHD $INO $PGEN Picks CODX fda approval at home tests BTAI earnings waiting for approval at 🏡 test INO earnings PGEN earnings

1 · Reply

CoffeeRocks May. 11 at 11:30 AM

$TRAW $VRAX $CODX $BTAI $INO Also TRAW could breakout

0 · Reply

CoffeeRocks May. 11 at 10:51 AM

$CODX $BTAI Following same pattern

0 · Reply

TraderNice May. 10 at 3:57 PM

$BTAI Guys, after reading different sources about the stock…there ATM is off. Watch the next 10 days this will float to $2.00. They finally coming around they get more money when the price rises than hamper down with a dumb ATM….i hate ATM! ATM always cripple the buyer’s profit.

0 · Reply

CoffeeRocks May. 10 at 3:09 PM

$CODX $BTAI

0 · Reply

TraderNice May. 10 at 12:13 AM

$BTAI The stock is going to be approved later this fall, the drug they using is already FDA approved! They are just wanting to be approved take it at home. Also, they have a new Commercialization Manager with 20+ years of experience. Giant market and the only FDA product in the game. Look at the reputable analysts, they have high analyst price

0 · Reply

AllAboutTheBread May. 9 at 9:23 PM

$BTAI i herd it supposed to hit 75.

0 · Reply

CoffeeRocks May. 9 at 3:39 PM

$JASMY.X $BIOLLM.X $BTAI

0 · Reply

CoffeeRocks May. 9 at 2:57 PM

$BTAI BioXcel Therapeutics (BTAI) has a few genuinely encouraging elements that investors often point to. The biggest driver is the potential expansion of IGALMI (BXCL501) into at-home treatment for agitation, which the FDA is already reviewing and could open up a massive market with tens of millions of addressable episodes each year. Despite recent dilution, several analysts still maintain Buy-level price targets well above current trading levels, arguing that the company’s long-term cash-flow potential is being undervalued. And beyond IGALMI, BioXcel continues to advance a broader neuropsychiatry pipeline - including programs in Alzheimer’s-related agitation, opioid withdrawal, and acute stress reactions - giving the company multiple shots on goal rather than relying on a single approval.

0 · Reply

TraderNice May. 9 at 5:58 AM

$BTAI BioXcel Therapeutics (BTAI) offers several encouraging factors for investors. The potential expansion of IGALMI (BXCL501) into at-home treatment for agitation, currently under FDA review, could open a massive market with tens of millions of addressable episodes annually. Despite recent dilution, analysts maintain Buy-level price targets due to the company’s undervalued long-term cash-flow potential. BioXcel also advances a broader neuropsychiatry pipeline, including programs in Alzheimer’s-related agitation, opioid withdrawal, and acute stress reactions, providing multiple shots on goal rather than relying on a single approval.

0 · Reply

wndyctyboy1975 May. 8 at 7:58 PM

$BTAI

0 · Reply

CoffeeRocks May. 8 at 4:15 PM

$BTAI $CODX $INHD $INO $PGEN

0 · Reply

11thestate May. 8 at 1:52 PM

The $9.75 million BioXcel Therapeutics ($BTAI) deadline is June 30, 2026 If you bought shares between March 9, 2023 through June 28, 2023, you are likely eligible for the $9.75 million recovery fund. This settlement resolves claims that BioXcel Therapeutics misled investors regarding internal controls, protocol adherence, and data integrity in its Phase 3 TRANQUILITY II clinical trial. The stock dropped 64% following the disclosure, and now the company is paying back to impacted shareholders ($1.52 per share). File your claim here: https://11th.com/cases/bioxcel-investor-settlement

0 · Reply

Washingtonstate May. 8 at 1:11 PM

$BTAI I

0 · Reply

CoffeeRocks May. 8 at 1:02 PM

$BTAI $CODX $INHD $INO $PGEN Let’s go let’s goooooooo

0 · Reply

Market Cap	32.49M
Revenue (ttm)	640,000.00
Net Income (ttm)	-69.90M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,921.88%
Debt to Equity Ratio	-1.15

Volume	340,600
Avg Vol	1,880,698
Day's Range	N/A - N/A
Shares Out	27.08M
Stochastic %K	42%
Beta	0.31
Analysts	Strong Sell
Price Target	$14.60